Skip to main content
. 2019 Jul 12;9:622. doi: 10.3389/fonc.2019.00622

Figure 3.

Figure 3

Correlation among circulating DNA markers measured at baseline (prior to regorafenib treatment). (A) Correlation between total amount of circulating DNA (measured as GE/ml) and cmDNA. (B) Correlation between cancer specific genetic alteration levels (RAS/BRAF mutant alleles) and cmDNA when both were positive.